Prostatic Neoplasms: Swerdloff RS

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 3 Articles   Help
A digest of articles written 1999 and later, on the topic "Prostatic Neoplasms," originating from Planet Earth —» Swerdloff RS.  Display:  All Citations ·  All Abstracts
1 Guideline ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. 2009

Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. · Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles BioMedical Research Institute, Torrance, CA 90509, USA. · Aging Male. · Pubmed #18763169 No free full text.

This publication has no abstract.

2 Review Transdermal androgens: pharmacology and applicability to hypogonadal elderly men. 2005

Swerdloff RS, Wang C. · Division of Endocrinology, Department of Medicine Harbor-UCLA Medical Center and Los Angeles Biomedical Research Center, Torrance 90509, USA. · J Endocrinol Invest. · Pubmed #16042369 No free full text.

Abstract: Transdermal testosterone (T) gels have proven to be an efficacious means of delivering T to hypogonadal men. Patches, gels and creams have been used in T transdermal formulations. Patches suffered from problems either with adherence or skin irritability while gels have a potential problem of transferability from patients to partner or other family member. At present, gels have been well received by clinicians and users. There is no evidence that transdermal preparations are not suitable for treatment of older hypogonadal men; the rapid off time of both patches and gels may argue allow that transdermal preparations may be a preferential treatment modality for older men with a potential higher risk of developing androgen-responsive prostate cancer.

3 Review Androgens and the ageing male. 2004

Swerdloff RS, Wang C. · Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA Harbor-UCLA Medical Center and Research Institute, Box 446, 1000 West Carson Street, Torrance, CA 90509-2910, USA. · Best Pract Res Clin Endocrinol Metab. · Pubmed #15261842 No free full text.

Abstract: Serum testosterone levels peak in early adulthood in men and fall progressively with age. Since sex hormone binding globulin increases with age, the unbound forms of testosterone (free and bioavailable testosterone) fall more steeply than total testosterone levels. Serum testosterone levels below the normal range for young healthy adult males provide chemical evidence of androgen deficiency independent of the age of the patient. When accompanied by signs or symptoms that are compatible with androgen deficiency, treatment with testosterone should be considered in older men without evidence of prostate or breast cancer. While such therapy for younger hypogonadal men has shown benefit on libido, mood, muscle mass, muscle strength, bone mineral density and haematocrit, similar benefits in older men have not been as adequately assessed. While there is no convincing evidence that testosterone treatment in older men will increase the risk of cardiovascular or prostate cancer, long-term, well-controlled studies are lacking and needed. Treatment options for older men include injectable, transdermal and transbuccal testosterone preparations.